Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DENALI THERAPEUTICS INC.

(DNLI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/20/2021 10/21/2021 10/22/2021 10/25/2021 10/26/2021 Date
44.75(c) 46.17(c) 47.8(c) 47.57(c) 47.91 Last
235 890 343 135 529 086 292 270 95 118 Volume
+1.06% +3.17% +3.53% -0.48% +0.71% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 93,6 M - -
Net income 2021 -247 M - -
Net cash position 2021 1 539 M - -
P/E ratio 2021 -24,2x
Yield 2021 -
Sales 2022 99,7 M - -
Net income 2022 -271 M - -
Net cash position 2022 1 479 M - -
P/E ratio 2022 -21,8x
Yield 2022 -
Capitalization 5 786 M 5 786 M -
EV / Sales 2021 45,4x
EV / Sales 2022 43,2x
Nbr of Employees 334
Free-Float 83,0%
More Financials
Company
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company clinical programs include leucine-rich repeat kinase 2 (LRRK2) inhibitor program, eukaryotic initiation factor 2 B (EIF2B) activator... 
More about the company
Ratings of Denali Therapeutics Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about DENALI THERAPEUTICS INC.
10/06DENALI THERAPEUTICS : Reports Phase 1 Results For Studies Targeting Amyotrophic Lateral Sc..
MT
10/06DENALI THERAPEUTICS : Announces Positive Clinical Results and Regulatory Progress for Deve..
AQ
10/06Denali Therapeutics Inc. Announces Positive Phase 1 Clinical Results and Regulatory Pro..
CI
10/05INSIDER SELL : Denali Therapeutics
MT
09/29DENALI THERAPEUTICS : Announces Upcoming Presentationsáon EIF2B Activator DNL343 and RIPK1..
AQ
09/27DENALI THERAPEUTICS : Appoints Katie Peng as Chief Commercial Officer
AQ
09/27Denali Therapeutics Inc Appoints Katie Peng as Chief Commercial Officer
CI
09/21DENALI THERAPEUTICS : Oppenheimer Initiates Coverage on Denali Therapeutics With Outperfor..
MT
09/09INSIDER SELL : Denali Therapeutics
MT
09/09DENALI THERAPEUTICS : Begins Dosing in Phase 1b Trial of Potential Drug for Amyotrophic La..
MT
09/09DENALI THERAPEUTICS : Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ..
AQ
09/09Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in..
CI
09/03INSIDER SELL : Denali Therapeutics
MT
09/01DENALI THERAPEUTICS : SMBC Nikko Starts Denali Therapeutics at Outperform with $78 Price T..
MT
08/26DENALI THERAPEUTICS : Announces Publication in Cell on New Approach to Treat FTD-GRN
AQ
More news
News in other languages on DENALI THERAPEUTICS INC.
10/06Denali Therapeutics annonce les résultats de la phase 1 de ses études sur la sclérose l..
09/09VENTE D'INITIÉS : Denali Therapeutics
09/09Denali Therapeutics commence le dosage dans l'essai de phase 1b d'un médicament potenti..
09/03VENTE D'INITIÉS : Denali Therapeutics
More news
Analyst Recommendations on DENALI THERAPEUTICS INC.
More recommendations
Chart DENALI THERAPEUTICS INC.
Duration : Period :
Denali Therapeutics Inc. Technical Analysis Chart | DNLI | US24823R1059 | MarketScreener
Technical analysis trends DENALI THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 47,57 $
Average target price 85,50 $
Spread / Average Target 79,7%
EPS Revisions
Managers and Directors
Ryan J. Watts President, Chief Executive Officer & Director
Steve E. Krognes Treasurer, Chief Financial & Accounting Officer
Vicki L. Sato Non-Executive Chairman
Carole Ho Chief Medical Officer & Head-Development
Dana Andersen CTO & Chief Manufacturing Officer
Sector and Competitors
1st jan.Capi. (M$)
DENALI THERAPEUTICS INC.-43.21%5 786
GILEAD SCIENCES, INC.16.15%84 845
BIONTECH SE261.78%71 229
WUXI APPTEC CO., LTD.24.08%64 399
REGENERON PHARMACEUTICALS19.27%59 906
VERTEX PHARMACEUTICALS-21.73%47 992